Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18754049 | NONIONIC POLYETHER SURFACTANTS | June 2024 | June 2025 | Allow | 11 | 1 | 0 | No | No |
| 18636731 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | April 2024 | February 2025 | Allow | 10 | 0 | 0 | No | No |
| 18598033 | METHOD FOR SEPARATING FLAVOKAWAIN AND KAVALACTONE, KAVALACTONE, AND MICROENCAPSULATED KAVALACTONE | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18392193 | SUBLINGUAL PHENTERMINE SPRAY COMPOSITIONS AND DAY-NIGHT APPETITE SUPPRESSION AND WEIGHT LOSS REGIMEN USING SAME | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18368099 | CRYSTALLINE HYDROCHLORIDE SALTS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | September 2023 | August 2024 | Allow | 11 | 2 | 1 | No | No |
| 18271534 | PYRROLOPYRIDINE DERIVATIVE PREPARATION METHOD | July 2023 | January 2026 | Allow | 30 | 1 | 0 | No | No |
| 18313920 | METHODS OF TREATING PATIENTS SUFFERING FROM A DISEASE CONDITION OR DISORDER THAT IS ASSOCIATED WITH AN INCREASED GLUTAMATE LEVEL | May 2023 | July 2025 | Allow | 26 | 2 | 1 | No | No |
| 18183247 | METHODS OF REDUCING THE LIKELIHOOD OF CARCINOID HEART DISEASE IN PATIENTS WITH NEUROENDOCRINE TUMORS | March 2023 | February 2026 | Allow | 35 | 4 | 0 | Yes | No |
| 18180181 | CDK Inhibitors And Their Use As Pharmaceuticals | March 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18172656 | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR | February 2023 | April 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18171822 | SUBLINGUAL PHENTERMINE SPRAY COMPOSITIONS AND DAY-NIGHT APPETITE SUPPRESSION AND WEIGHT LOSS REGIMEN USING SAME | February 2023 | March 2025 | Allow | 24 | 4 | 2 | Yes | No |
| 18106290 | METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | February 2023 | March 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18164286 | METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | February 2023 | August 2024 | Abandon | 19 | 2 | 0 | Yes | No |
| 18161402 | Scalp Numbing System | January 2023 | August 2024 | Abandon | 19 | 3 | 1 | No | No |
| 18099291 | PHARMACEUTICAL COMPOSITION FOR TREATING LOCALLY ADVANCED MISMATCH REPAIR-PROFICIENT/MICROSATELLITE STABLE (PMMR/MSS) COLORECTAL CANCER (CRC) AND USE THEREOF | January 2023 | June 2024 | Allow | 17 | 1 | 1 | No | No |
| 18154349 | TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS | January 2023 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18014882 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME | January 2023 | July 2025 | Allow | 30 | 0 | 0 | No | No |
| 17990321 | Drug delivery via contact lenses and similar ophthalmic devices | November 2022 | April 2024 | Abandon | 17 | 1 | 0 | Yes | No |
| 17926120 | DRUG DELIVERY SYSTEM BASED ON CALCIUM PHOSPHATE NANOPARTICLES FUNCTIONALIZED WITH BIOACTIVE COMPOUNDS FROM EUPHORBIA EXTRACT AND THE USES THEREOF | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17997807 | COMBINATIONS | November 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17972754 | Microemulsion Delivery Systems for Alcohol-Soluble Species Including DHEA, Pregnenolone, and Chrysin for Reducing Menopausal Symptoms | October 2022 | August 2025 | Allow | 33 | 3 | 1 | Yes | No |
| 18047497 | BACTERIAL NITRIC OXIDE SYNTHASE INHIBITORS | October 2022 | September 2024 | Allow | 23 | 1 | 1 | No | No |
| 17936508 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | September 2022 | January 2024 | Abandon | 16 | 0 | 1 | No | No |
| 17913916 | USE OF GABAA MODULATORS FOR TREATMENT OF RESPIRATORY CONDITIONS | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17906367 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | September 2022 | May 2025 | Allow | 32 | 0 | 0 | No | No |
| 17941611 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | September 2022 | June 2024 | Allow | 22 | 2 | 1 | No | No |
| 17821314 | METHODS OF IRON CATALYZED C-H BOND AMINATION | August 2022 | May 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17799611 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | August 2022 | January 2026 | Allow | 41 | 1 | 1 | No | No |
| 17866227 | IL-17 LIGANDS AND USES THEREOF | July 2022 | August 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17792304 | Substituted Pyrazolo-Pyrimidines and Uses Thereof | July 2022 | August 2025 | Allow | 37 | 1 | 0 | No | No |
| 17803393 | Magnolol and Sulforaphane Conjgate, and Preparation Method and Use Thereof | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17786309 | TETRAHYDROBENZO-QUINOLINE SULFONAMIDE DERIVATIVES USEFUL AS IGE MODULATORS | June 2022 | November 2025 | Allow | 41 | 2 | 0 | No | No |
| 17785155 | N-(3-AMINO-3-OXOPROPYL)-2-[(1-METHYL-4-NITRO-1H-IMIDAZOL-5-YL)THIO]BENZAMIDE AND ITS USE FOR TREATING HIV INFECTION | June 2022 | October 2025 | Allow | 41 | 1 | 1 | No | No |
| 17837458 | SHP1 AND SHP2 INHIBITORS AND THEIR METHODS OF USE | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17755716 | Methods of Treating Neurodegenerative Diseases Caused by G4C2 Expansion in C9ORF72 | May 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17595013 | PYRIDONE DERIVATIVE CRYSTAL FORM AND PREPARATION METHOD AND APPLICATION THEREFOR | April 2022 | August 2025 | Allow | 45 | 1 | 0 | No | No |
| 17724724 | COMPOUNDS AS LXR AGONISTS | April 2022 | June 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17766822 | Pyrimidine amide compounds and use thereof | April 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17760760 | METHOD FOR PRODUCING AROMATIC ASTATINE COMPOUND | March 2022 | October 2025 | Abandon | 43 | 3 | 1 | Yes | No |
| 17753645 | STABLE CRYSTALLINE APALUTAMIDE IN PURE FORM, AND PROCESS FOR THE PREPARATION THEREOF | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17632214 | AMINOSTEROL COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME | February 2022 | November 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17624692 | Composition Comprising at Least One Oxazoline for Inhibiting the Growth of Malassezia Yeasts Involved in Cradle Cap, in Particular | January 2022 | December 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17622608 | PROMOTING TISSUE REGENERATION | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17622042 | ARTEMISININ-DERIVATIVE N-HETEROCYCLIC CARBENE GOLD(I) HYBRID COMPLEXES | December 2021 | December 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17557567 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | December 2021 | May 2025 | Allow | 40 | 1 | 1 | No | No |
| 17619893 | MELANOCORTIN-4 RECEPTOR AGONISTS | December 2021 | December 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17617711 | ANTIBIOTIC POTENTIATION FOR NONTUBERCULOUS MYCOBACTERIAL DISEASE | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17535812 | METHOD OF ASYMMETRICALLY SYNTHESIZING NICOTINE | November 2021 | October 2025 | Allow | 46 | 2 | 1 | No | No |
| 17456033 | CANNABINOL-O-ACETATE SYNTHESIS, COMPOSITIONS, AND METHODS OF USE | November 2021 | February 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17609021 | PRODRUG COMPOUNDS | November 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17606247 | COMPOSITIONS FOR IMPROVING BRAIN HEALTH AND MEMORY | October 2021 | September 2025 | Allow | 47 | 2 | 1 | No | No |
| 17502038 | ANTI-AGING METHOD COMPRISING APPLYING JWA GENE | October 2021 | February 2026 | Allow | 52 | 3 | 1 | No | No |
| 17499248 | RESIQUIMOD TOPICAL AND INJECTABLE COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC SKIN CONDITIONS | October 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17492320 | ISOPROPYLCARBONATE BENZOYL PEROXIDE COMPOSITIONS AND METHODS OF USE | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17442631 | CHIAURANIB FOR TREATMENT OF SMALL CELL LUNG CANCER | September 2021 | August 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17442285 | SALTS OF 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROL-4-ONE COMPOUND AS ERK INHIBITORS | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17469765 | METHOD FOR TREATING FEMALE NON-SMOKERS WITH NON-SMALL CELL LUNG CANCER | September 2021 | December 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17436885 | SMALL MOLECULE MODULATORS OF IL-17 | September 2021 | August 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17436884 | COMPOSITIONS FOR PATHOGEN INACTIVATION OR PATHOGEN REDUCTION MANAGEMENT | September 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17433193 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | August 2021 | May 2025 | Allow | 45 | 2 | 1 | No | No |
| 17432851 | PHARMACEUTICAL COMPOSITION COMPRISING TETRAHYDROCANNABIVARIN FOR THE PREVENTION AND TREATMENT OF OVERWEIGHT | August 2021 | November 2025 | Allow | 51 | 4 | 0 | Yes | No |
| 17432485 | TREATMENT FOR RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR V (RORV) -DEPENDENT CANCERS | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17430219 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND RIBOCICLIB | August 2021 | February 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17428369 | METHOD FOR PRODUCING A COMPOSITION COMPRISING A 3-O-p-COUMAROYL ESTER OF TORMENTIC ACID FROM A PLANT CELL CULTURE, APPLICATIONS THEREOF AS ANTIPARASITIC AGENT FOR THE TREATMENT OF TRYPANOSOMIASIS | August 2021 | December 2025 | Allow | 52 | 3 | 1 | Yes | No |
| 17310268 | 15-PGDH INHIBITORS | July 2021 | November 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17425483 | COMPOSITIONS COMPRISING THYMOQUINONE AND ADDITIONAL BIOLOGICALLY ACTIVE COMPOUNDS | July 2021 | January 2026 | Allow | 54 | 2 | 1 | Yes | No |
| 17423778 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17374509 | NONIONIC POLYETHER SURFACTANTS | July 2021 | October 2024 | Abandon | 39 | 3 | 1 | No | No |
| 17422283 | NLRP3 MODULATORS | July 2021 | August 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17418323 | DIKETOPIPERAZINE DERIVATIVES AS CALCIUM ATPASE INHIBITOR FOR ENHANCING ANTICANCER ACTIVITY | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17350581 | Compounds, Compositions and Methods | June 2021 | August 2024 | Allow | 38 | 0 | 1 | No | No |
| 17349862 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | June 2021 | September 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17345688 | COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17413064 | COMPOSITION FOR PREVENTING OR TREATING CELLULAR SENESCENCE-RELATED DISEASES COMPRISING ZOTAROLIMUS AS ACTIVE INGREDIENT | June 2021 | September 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17413406 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT | June 2021 | December 2024 | Allow | 42 | 2 | 0 | No | No |
| 17312858 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | June 2021 | May 2024 | Allow | 35 | 2 | 1 | No | No |
| 17312077 | Aqueous Based Pharmaceutical Formulations of 1,2-Dihydropyridine Compounds | June 2021 | January 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17312196 | SALIVARY GLAND REGENERATION | June 2021 | January 2025 | Allow | 44 | 1 | 1 | No | No |
| 17255707 | PHARMACEUTICAL COMPOSITION CONTAINING 9-ETHYL-6, 6-DIMETHYL-8-(4-MORPHOLIN-4-YL-PIPERIDIN-1-YL)-11-OXO-6, 11-DIHYDRO-5H-BENZO[B]CARBAZOLE-3-CARBONITRILE | June 2021 | August 2024 | Allow | 43 | 3 | 0 | Yes | Yes |
| 17311105 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17299618 | CARBORANE COMPOUNDS, CARBORANE ANALOGS, AND METHODS OF USE THEREOF | June 2021 | September 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17299696 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | June 2021 | June 2024 | Allow | 36 | 1 | 1 | No | No |
| 17299741 | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR | June 2021 | June 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17299733 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | June 2021 | February 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17299634 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | June 2021 | November 2024 | Allow | 42 | 2 | 0 | No | No |
| 17295327 | METHODS OF TREATING CANCERS | May 2021 | April 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17293157 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | May 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17306167 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | May 2021 | December 2024 | Allow | 43 | 2 | 0 | No | No |
| 17290741 | METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA | April 2021 | August 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17288718 | DRUG FOR TREATING TINNITUS | April 2021 | November 2024 | Allow | 43 | 1 | 1 | No | No |
| 17287137 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | April 2021 | March 2024 | Allow | 35 | 1 | 0 | No | No |
| 17286002 | DEUTERATED MELFLUFEN COMPOUNDS | April 2021 | July 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17224902 | ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION | April 2021 | May 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17281525 | INDOLE MACROCYCLIC DERIVATIVE, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17280245 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | March 2021 | April 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17279765 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | March 2021 | June 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17278397 | NOVEL QUINAZOLINE EGFR INHIBITORS | March 2021 | July 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17277759 | COMPOSITIONS AND METHODS FOR INHIBITING ACSS2 | March 2021 | November 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17277706 | COMPOSITION FOR INHIBITION OR TREATMENT OF BRAIN TUMORS OR SYMPTOMS ATTRIBUTABLE THERETO | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17275918 | COMPOSITIONS AND METHODS FOR ENHANCING WOUND HEALING | March 2021 | June 2024 | Abandon | 39 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NOTTINGHAM, KYLE GREGORY.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner NOTTINGHAM, KYLE GREGORY works in Art Unit 1621 and has examined 72 patent applications in our dataset. With an allowance rate of 52.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner NOTTINGHAM, KYLE GREGORY's allowance rate of 52.8% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NOTTINGHAM, KYLE GREGORY receive 1.44 office actions before reaching final disposition. This places the examiner in the 23% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by NOTTINGHAM, KYLE GREGORY is 42 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +60.7% benefit to allowance rate for applications examined by NOTTINGHAM, KYLE GREGORY. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.2% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 75.0% of cases where such amendments are filed. This entry rate is in the 94% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.3% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.